Lapatinib and renal impairment: a case report

Tumori. 2013 May-Jun;99(3):e134-5. doi: 10.1177/030089161309900334.

Abstract

This clinical report describes durable control of disease in a postmenopausal patient receiving hemodialysis and letrozole plus lapatinib since the diagnosis of HER2-positive, estrogen receptor-positive liver metastasis from breast cancer after anastrozole plus trastuzumab failure.

Publication types

  • Case Reports

MeSH terms

  • Anastrozole
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / complications
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / secondary*
  • Drug Administration Schedule
  • Female
  • Glomerulonephritis, Membranoproliferative / complications*
  • Glomerulonephritis, Membranoproliferative / therapy
  • Humans
  • Lapatinib
  • Letrozole
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary*
  • Middle Aged
  • Nitriles / administration & dosage
  • Postmenopause
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Receptors, Estrogen / analysis
  • Renal Dialysis*
  • Trastuzumab
  • Treatment Failure
  • Treatment Outcome
  • Triazoles / administration & dosage
  • Ultrasonography

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Nitriles
  • Quinazolines
  • Receptors, Estrogen
  • Triazoles
  • Lapatinib
  • Anastrozole
  • Letrozole
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab